Stocks
Annexon, Inc.ANNX
NASDAQHealthcareBiotechnology$4.23
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing complement-based therapies for autoimmune and neurodegenerative diseases. Its lead candidate, ANX005, targets C1q and is in late-stage trials for Guillain-Barré syndrome, with additional programs in Huntington's disease and other indications. Investors track the company for its potential to address unmet needs in complement-mediated disorders.
52W Range: $2.54-$7.18
Congressional Interest in Annexon, Inc. (ANNX)
1 member of Congress has disclosed 1 trade in Annexon, Inc. (ANNX), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
1
Sells
0
Who in Congress Is Trading ANNX?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2017-11-22 | MICHAEL T. MCCAUL | buy | $1K-$15K |